Zobrazeno 1 - 10
of 22
pro vyhledávání: '"María, Navalón"'
Autor:
María Navalón Rubio, Carmen Jovani Casano, Marta Soria López, Alfonso Rodríguez Herrera, Miguel Ángel López Casado, Víctor Manuel Navas-López, Víctor Vila Miravet
Publikováno v:
Anales de Pediatría (English Edition), Vol 101, Iss 6, Pp 393-400 (2024)
Introduction: Paediatric gastrointestinal endoscopy (pGIE) has advanced significantly over the last decade, with increased diagnostic and therapeutic applications. Objectives: This study examines the current state of pGIE in Spain, changes in the fie
Externí odkaz:
https://doaj.org/article/b5c35813bdac4c07a955b76b59a07fb6
Autor:
Víctor Manuel Navas-López, Gemma Pujol Muncunill, Enrique Llerena, María Navalón Rubio, David Gil-Ortega, Vicente Varea-Calderón, Carlos Sierra Salinas, Javier Martin-de-Carpi
Publikováno v:
Anales de Pediatría, Vol 88, Iss 2, Pp 89-99 (2018)
Resumen: Introducción y objetivos: Adalimumab (ADA), anticuerpo anti-TNF-α monoclonal recombinante de origen humano, generalmente se emplea como tratamiento de segunda línea en niños con enfermedad de Crohn (EC) que no han respondido o han perdid
Externí odkaz:
https://doaj.org/article/2a51f5ebcd2c4d2d83f6d5f3cdf06fca
Autor:
Víctor Manuel Navas-López, Gemma Pujol-Muncunill, Enrique Llerena, María Navalón Rubio, David Gil-Ortega, Vicente Varea-Calderón, Carlos Sierra Salinas, Javier Martin-de-Carpi
Publikováno v:
Anales de Pediatría (English Edition), Vol 88, Iss 2, Pp 89-99 (2018)
Background and objectives: Adalimumab (ADA), a monoclonal humanised anti-TNF antibody, is usually prescribed as a second-line treatment in paediatric Crohn's disease (CD) patients who have become unresponsive or developed intolerance to infliximab (I
Externí odkaz:
https://doaj.org/article/5328894caf544dce826505f8eb781bb1
Autor:
María Navalón-López, Aurora Dols-Perez, Santiago Grijalvo, Cristina Fornaguera, Salvador Borrós
Publikováno v:
Nanoscale Advances. 5:1611-1623
Oligopeptide end-modified poly(β-amino ester)s (OM-pBAEs) offer a means for the effective implementation of gene therapeutics in the near future. A fine-tuning of OM-pBAEs to meet application requirements is achieved by the proportional balance of o
Autor:
Fernando Alberca-de-las-Parras, María Navalón-Rubio, Juan Egea-Valenzuela, Francisco-Javier Álvarez-Higueras, Gonzalo Antón-Ródenas, Miriam Alajarín-Cervera, Andrés Serrano-Giménez, David Gil-Ortega, María Muñoz-Tornero, Akiko Ono-Ono, Luis Fernando Carballo-Álvarez
Publikováno v:
Revista Espanola de Enfermedades Digestivas, Vol 107, Iss 4, Pp 240-242 (2015)
Direct percutaneous endoscopic jejunostomy (DPEJ) is an infrequent procedure as it is not always easy to obtain transillumination, being this the main reason for failure of this technique. In patients with previous surgery, this procedure is more com
Externí odkaz:
https://doaj.org/article/380f14e0ad54484a8af3d560f9fc8c62
Autor:
Meritxell Perramón, María Navalón, Guillermo Fernández Varo, Belén González, Alazne Moreno-Lanceta, Cristina Fornaguera, Pedro Melgar-Lesmes, Salvador Borrós, Wladimiro Jiménez
Publikováno v:
Journal of Hepatology. 77:S106
Autor:
Natalia Ruiz Santana, Marta Herrador López, Laura Camacho Martel, Rafael Martín-Masot, María Navalón Rubio, Víctor M Merino Valero, Guillermo Alcain Martinez, Sara N Ramos-Cózar, Víctor Manuel Navas-López, Verónica Ortega Doltz, Almudena Frías Arjona
Publikováno v:
Journal of pediatric gastroenterology and nutrition. 71(2)
"The IBD Classroom in Nature" is an initiative that combines training and leisure activities in an ideal environment where families and patients can interact with each other. The objective of the present study was to quantify the effect that "The IBD
Autor:
Javier Martín-de-Carpi, Gemma Pujol-Muncunill, Vicente Varea-Calderón, David Gil-Ortega, Carlos Sierra Salinas, María Navalón Rubio, Enrique Llerena, Víctor Manuel Navas-López
Publikováno v:
Anales de Pediatría (English Edition), Vol 88, Iss 2, Pp 89-99 (2018)
Background and objectives: Adalimumab (ADA), a monoclonal humanised anti-TNF antibody, is usually prescribed as a second-line treatment in paediatric Crohn's disease (CD) patients who have become unresponsive or developed intolerance to infliximab (I
Autor:
Javier Martín-de-Carpi, David Gil-Ortega, María Navalón Rubio, Gemma Pujol Muncunill, Enrique Llerena, Carlos Sierra Salinas, Víctor Manuel Navas-López, Vicente Varea-Calderón
Publikováno v:
Anales de Pediatría, Vol 88, Iss 2, Pp 89-99 (2018)
Resumen: Introducción y objetivos: Adalimumab (ADA), anticuerpo anti-TNF-α monoclonal recombinante de origen humano, generalmente se emplea como tratamiento de segunda línea en niños con enfermedad de Crohn (EC) que no han respondido o han perdid
Autor:
Juan Egea Valenzuela, Fernando Alberca de Las Parras, Jose Antonio Morilla Fernandez, David Gil Ortega, María Navalón Rubio, Borja Melero Nicolás, Tania Fernández Llamas
Publikováno v:
Revista Española de Enfermedades Digestivas.
caustic ingestion in children is rare but has potentially serious consequences.to analyze the clinical and endoscopic features and the type of caustic ingested in our population.the upper endoscopies performed in this setting, as well as the characte